167
Participants
Start Date
June 20, 2023
Primary Completion Date
August 19, 2025
Study Completion Date
June 30, 2026
Test group (Group A): FCN-159 8 mg, orally, once daily;
After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
Control group (Group B): Placebo, orally, once daily;
After completing all screening visit items, qualified patients will be randomly assigned to the test group (Group A) or control group (Group B) in a 2:1 ratio, and receive FCN-159 or placebo within 3 days after randomization.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
Plastic Surgery Hospital,Chinese Academy of Medical Sciences, Beijing
Nanfang Hospital, Southern Medical University, Guangzhou
Sun Yat-sen University Cancer Center, Guangzhou
Peking University Shenzhen Hospital, Shenzhen
The Fourth Hospital of Hebei Medical University, Shijiazhuang
The Second Hospital of Hebei Medical University, Shijiazhuang
Renmin Hospital of Wuhan University, Wuhan
TongJi Hospital，TongJi Medical College Huazhong University of Science and Technology, Wuhan
The First Hospial of China Medical University, Shenyang
Fudan University Shanghai Cancer center, Shanghai
West China Hospital，Sichuan University, Chengdu
Hangzhou First People's Hospital, Hangzhou
Zhejiang Provincial People'S Hospital, Hanzhou
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
INDUSTRY